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Background: Drugs for inhalation are the cornerstone of therapy in obstructive lung disease. We have observed
that up to 75 % of patients do not perform a correct inhalation technique. The inability of patients to correctly use
their inhaler device may be a direct consequence of insufficient or poor inhaler technique instruction. The objective
of this study is to test the efficacy of two educational interventions to improve the inhalation techniques in patients
with Chronic Obstructive Pulmonary Disease (COPD).
Methods: This study uses both a multicenter patients´ preference trial and a comprehensive cohort design with
495 COPD-diagnosed patients selected by a non-probabilistic method of sampling from seven Primary Care Centers.
The participants will be divided into two groups and five arms. The two groups are: 1) the patients´ preference
group with two arms and 2) the randomized group with three arms. In the preference group, the two arms
correspond to the two educational interventions (Intervention A and Intervention B) designed for this study. In the
randomized group the three arms comprise: intervention A, intervention B and a control arm. Intervention A is
written information (a leaflet describing the correct inhalation techniques). Intervention B is written information
about inhalation techniques plus training by an instructor. Every patient in each group will be visited six times
during the year of the study at health care center.
Discussion: Our hypothesis is that the application of two educational interventions in patients with COPD who are
treated with inhaled therapy will increase the number of patients who perform a correct inhalation technique by at
least 25 %. We will evaluate the effectiveness of these interventions on patient inhalation technique improvement,
considering that it will be adequate and feasible within the context of clinical practice.
Trial registration: Current Controlled Trials ISRTCTN15106246* Correspondence: mariap.barnestein.exts@juntadeandalucia.es
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Drugs for inhalation are the cornerstone of therapy in ob-
structive lung disease. Inhalers are the principle vehicles
for the effective administration of medication. They allow
high lung deposition of the drug and minimize systemic
adverse drug reactions [1,2]. The effectiveness of drugs for
inhalation can be influenced by many factors including
age, sex, education of the patient, duration of disease, type
of inhaler used, correct inhalation technique and use of
several inhalers [2,3].
There are three main categories of inhalers: pressurized
metered dose inhalers (pMDIs), dry powder inhalers
(DPIs) and small volume nebulizers (SVNs). DPIs and
pMDIs are the devices most commonly used for drug de-
livery in the treatment of asthma and COPD patients [1,2].
Technical features of inhaler devices have improved
over time. However, the effectiveness in delivering drugs
to the lung depends on correctly performed inhalation
maneuvers. Incorrect usage of inhalers is a significant
problem for both asthma and COPD management
because it may result in diminished therapeutic effects,
resulting in poor control of symptoms and thereby insuf-
ficient disease management [4-6]. As a result, patients
might receive treatment, but without proper education
and training in correct inhalation techniques, the thera-
peutic benefit is less than optimal [2].
In a previous study, we observed that up to 75 % of
patients do not perform a correct inhalation technique
(data not published) and other studies show a similar
percentage of error [7-9]. Many inhalers are complicated
to use and some require up to eight steps [1].
Efficient use of pMDIs requires coordination between
simultaneous inhalation and device actuation, a slow and
continuous inspiratory flow rate during inhalation fol-
lowed by a breath hold of at least ten seconds. Patients
frequently fail to exhale fully before inhalation, they acti-
vate the device before or at the end of inhalation, or
while breath-holding. Other common errors are high in-
spiratory flows, not shaking the device before use and
stopping inspiration when the spray collides with the
throat. Other drawbacks of these devices are that they
contain environmentally unfriendly propellants and most
of them provide no dose counter, so the patients do not
know the number of doses remaining and they use the
device when it is empty [1,9,10].
The use of DPIs removes the coordination problem;
however mistakes in the inhalation techniques are high.
The most common errors are: not placing the device
correctly, exhaling into the mouthpiece, low inspiratory
flows and incorrect breath-holding. The most critical
mistakes may be exhalation into the mouthpiece and low
inspiratory flow, because the humidity and inadequate
flow reduce the amount of drug released and its ability
to reach the lungs [1,10].Other factors associated with improper use of devices in
patients with COPD are related to age and cognitive status
[11,12], the number of devices [10,13] and the training of
healthcare professionals. Healthcare personnel responsible
for teaching the correct use of inhalation devices are lacking
in basic knowledge and user skills [10,14]. To acquire the
skills for using these devices, health professionals and
patients must be adequately educated and trained [15,16].
The inability of patients to use their inhaler device cor-
rectly may be a direct consequence of insufficient or
poor inhaler technique instruction. The quality of the
initial instruction is of paramount importance for the
outcome of inhalation therapy. Written instruction alone
is insufficient in teaching correct inhalation techniques.
Verbal instruction and technique assessment and
reassessment are essential for patients to achieve a proper
technique [17]. Patients who receive inhalation instructions
at least once more after the initial instruction have better
inhalation techniques compared with those who only re-
ceive instruction at the time of prescription [18]. Training
in correct inhaler use rather than instructor demonstration
appears to be important [19,20].
The objective of this study is to test the efficacy of two
educational interventions to improve inhalation techniques
in patients with COPD.
Methods
This study has been approved by the Ethical Committees
of Distrito Sanitario Málaga (01/03/07) and Axarquía
(13/05/08).
Participants
A total of 495 patients with COPD selected by a non-
probabilistic consecutive sampling method from seven
Primary Care Centers will participate in the study. The
inclusion criteria will be: having been diagnosed with
COPD by spirometry following the SEPAR (Sociedad
Española de Neumología y Cirugia Torácica) guidelines
[21], receiving clinical assistance in primary care centers
in the Malaga area, having been prescribed inhalation
treatment, and having agreed to be part of the study by
giving signed written consent. Exclusion criteria will be:
other respiratory conditions which are not included in
the COPD definition (bronchiectasis, asthma or cystic fi-
brosis) and cognitive impairment problems registered in
their clinical record (dementia, Alzheimer, Parkinson,
cognitive decline). All these criteria will be reviewed in
the patients´ clinical record.
Sample size
This was calculated to detect a correct inhalation tech-
nique percentage difference between groups of 25 %,
with a statistical power of 80 % and a confidence level of
95 %, assuming a percentage of expected losses of 40 %.
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the selection criteria mentioned above. In the Randomized
group it will be necessary to include 297 patients, and in
the Preferences group 198 (99 patients per arm).
Design
The study is structured as a multicenter patients´
preference trial or a comprehensive cohort design
(Figure 1). The patients will be divided into two
groups:
– Randomized patients: randomized control trial
(RCT) group with three arms (control, intervention
A and intervention B)Figure 1 Study general graphic.– Patients with preferences: PPS group with two arms
(intervention A and intervention B)
Patients without strong preferences for a treatment are
randomized and those with strong preferences are given
their choice. Such a design enables comparisons between
patients with and without a preference and an ex-
ploration of patient characteristics associated with
preference [22,23].Setting
The study will take place in primary care facilities in
Malaga, Spain.
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Primary outcome
Performance of correct inhalation techniques. The correct
inhalation techniques will be measured by an investigator
following SEPAR guidelines [1].
Secondary outcome
Participants will be evaluated using inhalatory pick flow,
functional status (spirometry), mental-cognitive status
(Mini-mental Status Examination test), dyspnea with Base-
line Dyspnea Index (BDI) [24] and Modified Medical
Research Council (MMRC) [25]; questionnaires of quality
of life (St George respiratory questionnaire [26], and
EuroQoL-5D [27]) and the clinical progress of illness
(Seguimiento Clínico en EPOC: SeguiEPOC questionnaire).
Independent variables
Independent variables will be: age, sex, educational level,
comorbidity, smoking history, COPD severity grade
(according to SEPAR guidelines [28]), prescribed medica-
tion, family support (Family Apgar Test [29]): and social
support (DUKE-UNC Test [30]).
Intervention
We have designed two educational interventions:
Intervention A: written information.
We will give written information about inhalation
techniques to the patient. We will design a leaflet about
the correct inhalation techniques containing the main
devices the patients use in our area. We will include four
devices: Handihaler, Turbuhaler, Accuhaler and pMDI.
We will describe all the steps necessary to perform the
correct technique including images to illustrate the most
relevant ones.
The patients included in this group will be asked how
they use their inhalers and the interviewer will write
down the mistakes in a template designed to follow the
SEPAR guidelines [1]. When the inhalation techniques
have been performed, the interviewer will give the leaflet
to the patients and will invite them to read it and to
identify differences between the steps of the correct in-
halation technique (leaflet) and the technique they have
performed.
In the follow-up visits we will ask the patients about
the leaflet and about the differences they have found.
Intervention B: written information about inhalation
techniques plus instructor training.
We will give written information about the inhalation
technique to the patient (leaflet described above) and we
will train the patient about correct inhalation techniques.
The training of instructors in the use of inhaler devices
has been carried out at the Pediatrics Neumology Serviceof Hospital Materno Infantil (Málaga). We will perform
training in three steps:
– Patients will be asked how they use their inhalers.
Using a variety of placebo inhalers, all of them will
demonstrate, to the instructor, how they use their
inhalers.
– When the patient has given the demonstration, the
trainer will ask about the problems and perceived
mistakes with the technique.
– The trainer will demonstrate the proper technique.
Each device will be used and its technique will be
explained step by step. The importance of following
the correct technique every time the patient uses the
inhaler device will be emphasized.
Finally, the patients can ask questions and they will
practice the techniques until they are correct or until the
patient becomes tired.
In the follow-up visits we will review the inhalation
technique and we will correct any mistakes or clear up
any doubts as explained previously. The objective here is
for the patients to identify their mistakes, and if they
cannot, to remind them of the proper technique by giving
as many demonstrations as necessary.
Recruitment
Patients will be contacted using their health center
records. They will be invited to participate in the study
after a brief explanation by telephone about the research
aims and they will receive an appointment in the health
center. At this first appointment (inclusion visit) patients
will receive more detailed information about the study
and, if they agree to participate, they will sign the written
consent.
At this point, subjects will be asked whether they have
a preference for one of the interventions and they will be
divided into two groups (Figure 1). Those who select the
preference group choose their intervention and they will
form two arms of the study. The participants without a
preference will join the randomized group and they will
be randomly allocated into the three arms of this group.
In the preferences group, the two arms correspond to
the two educational interventions designed for this study.
In the randomized group the three arms will be: inter-
vention A, intervention B and a control arm.
The randomization will be made using the block
randomization technique. The blocks consist of six
patients, two subjects per group or three patients, one
patient per group (Intervention A, Intervention B and
control). The blocks will be marked with a number from
1 to 96 and they will be chosen at random to create the
allocation sequence using a sequence of random num-
bers generated by the Microsoft Excel 2003 program
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group will be made by contacting the person responsible
for random sequence by phone. Because the patients are
from various health centers, the randomization and the
presence of the two interventions and control subjects in
all the health centers will be guaranteed.
After randomization all the study data will be recorded
and the performance of correct inhalation techniques
will be measured in all groups (inclusion visit). In the
case of the control group, the inhalation techniques will
be tested asking them about how they use their inhalers
and the interviewer will write down the mistakes in the
template designed. The interviewer will only correct the
critical mistakes. In the follow-up visits the subjects will
be invited to perform the inhalation technique and the
mistakes will be written down.Follow-up
All study groups will undergo the same follow up: five
visits during one yearControl group
Visit one will take place one month after the inclusion
visit. Primary and secondary outcomes will be measured
(excluding spirometry and quality of life).
Visit two will take place three months after the inclu-
sion visit. All the study data will be recorded.
Visit three will take place six months after the inclu-
sion visit. Primary and secondary outcomes will be mea-
sured (excluding spirometry and quality of life).
Visit four will take place 12 months after the inclusion
visit. All the study data will be recorded.Intervention A group
Visit one will take place one month after the inclusion
visit. Primary and secondary outcomes will be measured
(excluding spirometry and quality of life) and correct in-
halation techniques using the designed leaflet will be
encouraged.
Visit two will take place three months after the inclu-
sion visit. All the study data will be recorded and correct
inhalation techniques using the designed leaflet will be
encouraged.
Visit three will take place six months after the inclusion
visit. Primary and secondary outcomes will be measured
(excluding spirometry and quality of life) and correct in-
halation techniques using the designed leaflet will be
encouraged.
Visit four will take place 12 months after the inclusion
visit. All the study data will be recorded and correct in-
halation techniques using the designed leaflet will be
encouraged.Intervention B group
Visit one will take place one month after the inclusion
visit. Primary and secondary outcomes will be measured
(excluding spirometry and quality of life), correct inhal-
ation techniques using the leaflet will be encouraged and
training by the monitor will focus on motivational
aspects.
Visit two will take place three months after the inclu-
sion visit. All the study data will be recorded and correct
inhalation techniques (using both the leaflet and the
training) will be encouraged.
Visit three will take place six months after the inclusion
visit. Primary and secondary outcomes will be measured
(excluding spirometry and quality of life) and correct in-
halation techniques using the leaflet will be encouraged
and training by the monitor will focus on motivational
aspects.
Visit four will take place 12 months after the inclusion
visit. All the study data will be recorded, correct inhalation
techniques using the leaflet will be encouraged and the
training with the monitor will focus on motivational
aspects.
Statistical analysis
A descriptive statistical analysis will be performed for all
the study variables. We will calculate the mean, median
and standard deviations for quantitative variables, and
the absolute and relative frequency for qualitative
variables.
The 95 % confidence interval will be applied. The analysis
will be made following an intention-to-treat procedure.
The baseline comparison will be made between the main
variables that we expected to be related to the primary out-
come using the Chi-Square test or an analysis of variance
(ANOVA).
The between-group comparison for the primary out-
come will be explored using the Chi-Square Test. The
Relative Risk Reduction (RRR), the Absolute Risk Reduc-
tion (ARR) and the Number Needed to Treat (NNT) will
be calculated. Inferences for the secondary outcomes will
be made using an ANOVA or Chi-Square test. Each
group will be analyzed separately. The comparison using
PPS groups is unreliable because of the presence of un-
known and uncontrolled confounders. It is necessary to
make a comparison between RCT groups alone and ana-
lyses which include the PPS groups should be treated as
observational studies with known confounding factors
adjusted for in the analysis. Then the analysis will be per-
formed following the next steps:
– Comparison in RCT group: this will be made
between each intervention arm versus control arm
(intervA versus control; intervB versus control) and
between intervention A and intervention B.
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be performed between the intervention arms of each
group (intervA RCT group versus intervA PPS group;
intervB RCT group versus intervB PPS group).
Finally, a logistic regression model will be performed for
the primary outcome (performance of correct inhalation
technique (yes/no)), considering the intervention as the
predictive variable and the rest of the independent mea-
sures as the possible modifying factors. We will use the
usual 5 % significance level (α=0.05) and the SPSS statis-
tical package, version 15.0, to run the proposed analysis.
Study limitations
The first limitation that we consider is due to the design
of study. Designs that allow participants to choose their
treatment are susceptible to confounding factors (including
the preference of patients). That is, the characteristics of
subjects who choose one treatment may differ from those
who choose the other in ways that are related to the out-
comes of interest. This weakens the internal validity of the
experiment and makes it impossible to isolate the ‘pure’
effect of the respective treatments [31] although this can be
controlled with the comparison of characteristics between
groups. Related to external validity, almost all eligible
patients enter the study, allowing examination of patient
characteristics with all the strengths of preferences [32].
As patients’ preferences have a ‘therapeutic effect’ on
compliance and motivation, we think they can have a posi-
tive effect on patients´ inhalation skills. These effects are
similar to the placebo effect [32]. Another related aspect is
the Hawthorne effect during the course of the study (that
is, the tendency of subjects participating in a research
study to change their behavior). Although this could affect
overall estimates of the adherence, the implications might
be less important in comparing results between the inter-
vention and the control group; furthermore, it is difficult
to perceive that any potential Hawthorne effect would be
maintained over the many months of this study. Both
effects will be taken into account during the analysis.
Another limitation is the selection bias due to missing
data. In order to diminish this bias, we will apply several
strategies:
– An increase of 40 % in the sample size (expected
losses)
– Three phone calls on different days and times for
unreachable patients
– Rescue appointments for those who do not attend
scheduled visits (three different appointments)
In addition, we take into account the possible contam-
ination between the control and the intervention group
because of the relationship between subjects in their
daily life (neighborhood, relatives, social networks orassociations). However, in another educational interven-
tion study performed with obese patients in our area we
did not find a significant level of this effect [33]. We also
believe that the intervention characteristics (several steps
and individual visits) that we have described will have
little influence on contamination between groups.
Another important aspect to consider is the protocol
and the intervention standardization. This is why the
dynamic has been structured in an exhaustive way and
the intervention will be performed by two professionals
trained in communication, disease knowledge and inhal-
ation techniques of the different devices used by COPD
patients. Furthermore, we have designed a manual for
the researchers where we explain the working plan, the
different parts of the intervention, the protocol scheme
to know what they have to measure each time and the
details to assess each variable included in the study. In
this way, the procedure can be replicated elsewhere.
Discussion
We designed and developed a multifactor intervention to
improve adherence in COPD, the ICEPOC study [34].
This study permitted us to analyze deeply the motives
and barriers or difficulties that these patients have in
complying with the recommended medication regimens.
This multifactor intervention included training about in-
halation techniques and we could see that up to 75 % of
patients do not perform a correct inhalation technique.
When the intervention was finished only 17 % did not
perform a correct inhalation technique (data not pub-
lished). Based on this observation, our hypothesis is that
the application of two educational interventions in
patients with COPD who use inhaled therapy is going to
improve by at least 25 % the number of patients who
perform the inhalation technique correctly.
RCT are regarded as the gold standard for assessing
the effectiveness of treatments. Random allocation of
patients reduces the probability that bias will affect the
outcome of the trial [35]. Such designs have the power
to eliminate a variety of alternative explanations for
changes in health-related measures over time, permitting
the researcher to reasonably conclude that the interven-
tion itself caused the changes. Although random alloca-
tion is intended to evenly distribute characteristics of
participants that may affect outcome and to remove se-
lection bias, it may not deal with other potential biases.
One of these is patients’ preferences [22]. Because
patients’ preferences are not dealt with in the
randomization process, they are viewed as a potential
threat to the validity of trials [23]. The effect of patients’
preferences on treatment outcomes in RCTs is, however,
uncertain [22].
Patients with strong preferences may decline to par-
ticipate. In a trial in which strong preferences exist and
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external validity will be adversely affected. When this
occurs, generalizability of the results to a wider popula-
tion will be limited. If patients with preferences consent
to randomization, this may also affect internal validity of
the trial. In this case some patients will receive their pre-
ferred treatment and others will not. Those who receive
their preferred treatment might be better motivated and
comply better with the treatment programs and report
better outcomes [32]. On the other hand, patients who
do not receive their preferred treatment may experience
‘resentful demoralization’ and may be less motivated,
less adherent to the treatment program, and even drop
out of the trial. The effects of preference are likely to be
more apparent in unblinded trials, such as educational
interventions, in which patients are aware of the treat-
ment they are receiving and the outcome measure is
subjective and self reported by them [22]. Additionally,
the opportunity to choose a treatment based on personal
preferences may enhance an individual’s sense of control
over the learning process within the context of an
educational/behavioral program, thereby increasing
self-efficacy for changes in behavior and resulting in
enhanced outcomes.
One approach to dealing with patients’ preferences is
the partially randomized preference design also known
as a patient preference trial or comprehensive cohort
design [23,32]. Patient preference design complements,
but does not replace randomized trials. In this way the
design of our study includes a preference group and a
randomized group. We have calculated that 99 patients
need to be included in each arm, both in the RCT group
(three arms) and in the PPS group (two arms). As it is
possible that we will find more patients with preferences
by any of the interventions, we have established an upper
limit in the preference group of 120 patients per arm; so,
if we get this number of patients included in any prefer-
ence arm we will stop the inclusion of additional patients
in this group.
Measuring patient preferences within a fully rando-
mized design deserves further use as this conserves all
the advantages of a fully randomized design with the
additional benefit of allowing for the interaction between
preference and outcome to be assessed [36]. With the
trend toward active patient participation in health care
decisions, it is likely that such preferences may be a key
factor in determining the effectiveness of health educa-
tion programs. The preference trial is an alternative to
the RCT because it is more similar to decision-making
in a clinical setting [31].
Trial status
The TECEPOC study is in an activating recruiting phase
since 2010.This study has been approved by the Ethical Committees
of Distrito Sanitario Málaga (07/07/2009) and Axarquía
(16/02/2010) and by Committee of Clinical Trials of Comu-
nidad Autónoma de Andalucía (25/01/2011). Subjects will
give their informed consent before being enrolled in the
study. Study completion date is estimated to be January
2013. Current Controlled Trials ISRTCTN15106246
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